A Phase I/IIa, Dose-Ranging Safety and Efficacy Study of Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Resiquimod (Primary)
- Indications Cutaneous T-cell lymphoma
- Focus Adverse reactions
- 13 Aug 2019 Biomarkers information updated
- 05 Sep 2012 New trial record